COVID-19 may have a mild course in the immunocompromised children

Researchers from 25 countries responded to a flash survey on the current incidence and severity of COVID-19 among children who receive anti-cancer chemotherapy, organized by doc. MUDr. Ondřej Hrušák, PH.D., from the Second Faculty of Medicine and his colleagues.

Researchers from 25 countries responded to a flash survey on the current incidence and severity of COVID-19 among children who receive anti-cancer chemotherapy. The responders currently follow approximately 10,000 children who are at risk for acquiring infections including COVID-19. About 200 children have been tested for COVID-19 so far and 9 of them were positive. Of these, 8 had a mild or asymptomatic course and 1 was just diagnosed at the time of the survey. Thus, although immunity is quite significantly suppressed in these children, course of their COVID-19 is often mild.

  • Flash survey was used to get data on COVID-19 incidence and severity
  • Pediatric Hem/Onc departments of 25 countries responded
  • COVID-19 may have a mild course in these immunocompromised children
  • Precautions should be taken to prevent any infections including COVID-19
  • Malignancy is a primary danger; preventive measures should not hinder its treatment

The article will be published at European Journal of Cancer (IF 6.68).

Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment

Published: 30. 3. 2020 / Last update: 30. 3. 2020 / Responsible person: Mgr. Ing. Tereza Kůstková